An official website of the United States government
Home
| HCPCS | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Drug Class | Minor Drug Class | Oral (Y/N) | FDA Approval Year | FDA Discontinuation Year | CMS Effective Date | CMS Discontinuation Date | Status |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| A9607 | Lutetium Lu 177 vipivotide tetraxetan | PLUVICTO | 1 millicurie | Radiopharmaceutical | Radiopharmaceutical | In Use | ||||||
| J9311 | Rituximab and Hyaluronidase | Rituxan Hycela | 10mg | Immunotherapy | Monoclonal Antibody | CD20 | No | 2017 | Jan 1, 2019 | In Use | ||
| C9110 | Alemtuzumab | Lemtrada | 10 mg | Immunotherapy | Monoclonal Antibody | CD52 | No | 2001 | Jan 1, 2001 | Dec 31, 2007 | No Longer Used | |
| S0116 | Bevacizumab | Avastin | 100 mg | Immunotherapy | Monoclonal Antibody | VEGFR | No | 2004 | Jul 1, 2004 | Jun 30, 2006 | No Longer Used | |
| C9302 | Zanidatamab-hrii | ZIIHERA | 2mg | Immunotherapy | Bispecific Antibody | HER2 | No | 2024 | Mar 26, 2025 | May 13, 2025 | No Longer Used | |
| J9298 | Nivolumab & Relatlimab-rmbw | Opdualag | 3mg/1mg | Immunotherapy | Checkpoint Inhibitor, Monoclonal Antibody | PD-1, LAG3 | No | 2022 | Sep 27, 2022 | In Use | ||
| Q5118 | Bevacizumab-bvzr | Zirabev | 10mg | Immunotherapy | Monoclonal Antibody | VEGFR | No | 2019 | Oct 1, 2019 | In Use | ||
| C9076 | Lisocabtagene maraleucel | Breyanzi | Immunotherapy | CAR-T | CD19 | No | 2021 | Jul 23, 2021 | Sep 27, 2021 | No Longer Used | ||
| J9308 | Ramucirumab | Cyramza | 5mg | Immunotherapy | Monoclonal Antibody | VEGFR | No | 2014 | Jan 1, 2016 | In Use | ||
| J1326 | Zolbetuximab-clzb | Vyloy | 2mg | Immunotherapy | Monoclonal Antibody | CLDN18.2 | No | 2024 | May 13, 2025 | In Use | ||
| Q5126 | Bevacizumab-maly | Alymsys | 10mg | Immunotherapy | Monoclonal Antibody | VEGF | No | 2022 | Nov 28, 2022 | In Use | ||
| Q2057 | Afamitresgene autoleucel | Tecelra | per therapeutic dose | Immunotherapy | T Cell Receptor (TCR) | MAGE-A4 | No | 2024 | Mar 26, 2025 | In Use | ||
| C9301 | Obecabtagene car pos t (Obecabtagene autoleucel) | AUCATZYL | up to 400 million | Immunotherapy | CAR-T | CD-19 | No | 2024 | Mar 26, 2025 | May 13, 2025 | No Longer Used | |
| J9216 | Interferon Gamma-1b | Actimmune | 3 million units | Immunotherapy | Cytokine | Interferon | No | 1999 | Jan 1, 2009 | In Use | ||
| C9169 | Nogapendekin alfa inbakicept-pmln | Anktiva | 1 microgram | Immunotherapy | Cytokine | IL-15 (⍺,β,ɣ) | No | 2024 | Sep 11, 2024 | Mar 26, 2025 | No Longer Used | |
| J9275 | Zanidatamab-hrii | ZIIHERA | 2mg | Immunotherapy | Bispecific Antibody | HER2 | No | 2024 | May 13, 2025 | In Use | ||
| C9174 | Datopotamab Deruxtecan | Datroway | 1mg | Immunotherapy | Drug Antibody Conjugate | Topoisomerase I | No | 2025 | May 13, 2025 | In Use | ||
| J9382 | Zenocutuzumab-zbco | Bizengri | 1mg | Immunotherapy | Bispecific Antibody | HER2, HER3 | No | 2024 | May 13, 2025 | In Use | ||
| C9142 | Bevacizumab-maly | Alymsys | 10mg | Immunotherapy | Monoclonal Antibody | VEGF | No | 2022 | Sep 27, 2022 | Dec 21, 2022 | No Longer Used | |
| J0202 | Alemtuzumab | Lemtrada | 1 mg | Immunotherapy | Monoclonal Antibody | CD52 | No | 2001 | Jan 1, 2016 | In Use | ||
| J9024 | Atezolizumab, hyaluronidase-tqjs | Tecentriq Hybreza | 5mg | Immunotherapy | Checkpoint Inhibitor | PD-L1 | No | 2024 | Mar 26, 2025 | In Use | ||
| Q5123 | Rituximab-arrx | Riabni | 10mg | Immunotherapy | Monoclonal Antibody | CD20 | No | 2021 | Jul 23, 2021 | In Use | ||
| J9022 | Atezolizumab | Tecentriq | 10mg | Immunotherapy | Checkpoint Inhibitor | PD-L1 | No | 2016 | Jan 1, 2018 | In Use | ||
| Q2024 | Bevacizumab | Avastin | 0.25 mg | Immunotherapy | Monoclonal Antibody | VEGFR | No | 2004 | Oct 1, 2009 | Dec 31, 2009 | No Longer Used | |
| Q5107 | Bevacizumab-awwb | Mvasi | 10mg | Immunotherapy | Monoclonal Antibody | VEGFR | No | 2018 | Jan 1, 2019 | In Use |
The use of NA indicates that the HCPCS code was Not Available. NA may mean that a) the HCPCS code has
not yet been created (new drug), b) the drug is given as an oral drug or alternative route (only in
specific instances are HCPCS assigned to these medications), or c) the HCPCS could not be found or is
truly not available.
